-
Adicet Bio NASDAQ:ACET Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Location: 500 Boylston St Fl 12, Massachusetts, 02116-3740, US | Website: www.adicetbio.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-89.58M
Cash
224.1M
Avg Qtr Burn
-22.75M
Short % of Float
5.99%
Insider Ownership
1.59%
Institutional Own.
76.37%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Lupus nephritis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1 Data readout | |
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Data readout | |
ADI-270 Details Cancer, Solid tumor/s, Hematologic malignancies | Phase 1 Initiation |